Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
Símbolo de cotizaciónRYTM
Nombre de la empresaRhythm Pharmaceuticals Inc
Fecha de salida a bolsaOct 05, 2017
Fundada en2013
Director ejecutivo- -
Número de empleados283
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 05
Dirección222 Berkeley Street
CiudadBOSTON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02116
Teléfono18572644280
Sitio Webhttps://rhythmtx.com/
Símbolo de cotizaciónRYTM
Fecha de salida a bolsaOct 05, 2017
Fundada en2013
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos